XM does not provide services to residents of the United States of America.
F
F

FreseniusMedical

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement With Premier, Inc.

BRIEF-Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement With Premier, Inc. Nov 19 (Reuters) - FRESENIUS MEDICAL CARE AG FMEG.DE : FRESENIUS MEDICAL CARE AWARDED MECHANICAL CIRCULATORY SUPPORT AGREEMENT WITH PREMIER, INC. FOR THE NOVALUNG® ECMO SYSTEM Source text: ID:nPnbNNcK4a Further company coverage: FMEG.DE (Gdansk Newsroo
F

Fresenius soars on Q3 beat across the board

BUZZ-Fresenius soars on Q3 beat across the board ** German healthcare company Fresenius FREG.DE rises 6.6% after the company reported better-than-expected third-quarter results . ** The company reported a 7% increase in group revenues to 5.3 billion euros and a 8% increase in adjusted EBIT, which came in at 552 million euros. ** The results were "ahead of consensus expectations across the board", Berenberg said ** "The better-than-expected performance was driven by core operating performance and
F
F
G

Elisa, Nexus, Telia

EUROPE RESEARCH ROUNDUP-Elisa, Nexus, Telia Nov 6 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Elisa, Nexus and Telia on Wednesday. HIGHLIGHTS * Elisa Oyj ELISA.HE : Barclays raises to overweight from underweight * Inficon Holding AG IFCN.S : Berenberg raises to buy from hold * Nexus AG NXUG.DE : Stifel cuts to hold from buy * Telenor ASA TEL.OL : Barclays cuts to equal weight from overweight * Telia TELIA.ST : Barclays cuts to u
3
A
A
A
B
B
B
B
C
D
D
E
E
H
H
H
T
T
T
A
B
F
R
S

Germany's Fresenius raises 2024 forecast after Q3 beat

UPDATE 2-Germany's Fresenius raises 2024 forecast after Q3 beat, shares rise Adds share move in paragraph 4, analyst comment in paragraph 6, FMC result in paragraph 7, net debt in paragraph 8, savings objective in paragraph 11 By Tristan Veyet and Rafal Wojciech Nowak Nov 6 (Reuters) - Germany's Fresenius FREG.DE raised its full-year outlook on Wednesday after beating third-quarter expectations, citing strong performances at its Kabi and Helios divisions and deleveraging efforts paying off , sen
F
F

Fresenius Medical Care AG reports results for the quarter ended in September 30 - Earnings Summary

Fresenius Medical Care AG reports results for the quarter ended in September 30 - Earnings Summary Fresenius Medical Care AG FMEG.DE reported quarterly adjusted earnings of 82 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 57 cents. The mean expectation of seven analysts for the quarter was for earnings of 65 cents per share.
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.